The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of CureVac N.V (NASDAQ: CVAC) closed at $5.12 in the last session, up 0.20% from day before closing price of $5.11. In other words, the price has increased by $0.20 from its previous closing price. On the day, 0.51 million shares were traded. CVAC stock price reached its highest trading level at $5.195 during the session, while it also had its lowest trading level at $5.1.
Ratios:
We take a closer look at CVAC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.69 and its Current Ratio is at 3.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On April 25, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $12 to $4. On June 08, 2023, SVB Securities started tracking the stock assigning a Outperform rating and target price of $13.SVB Securities initiated its Outperform rating on June 08, 2023, with a $13 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 07 ’25 when Thaminda Ramanayake bought 6,986 shares for $3.34 per share.
Myriam Mendila bought 17,839 shares of CVAC for $88,019 on Jan 07 ’25. On Jan 07 ’25, another insider, Pierre Kemula, who serves as the affiliate of the company, bought 51,523 shares for $4.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 1152884480 and an Enterprise Value of 545422336. As of this moment, CureVac’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.16. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.23 while its Price-to-Book (P/B) ratio in mrq is 1.13. Its current Enterprise Value per Revenue stands at 7.71 whereas that against EBITDA is 2.816.
Stock Price History:
The Beta on a monthly basis for CVAC is 1.83, which has changed by 0.6202532 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, CVAC has reached a high of $5.72, while it has fallen to a 52-week low of $2.47. The 50-Day Moving Average of the stock is -3.31%, while the 200-Day Moving Average is calculated to be 9.92%.
Shares Statistics:
According to the various share statistics, CVAC traded on average about 861.82K shares per day over the past 3-months and 1909370 shares per day over the past 10 days. A total of 225.17M shares are outstanding, with a floating share count of 96.01M. Insiders hold about 57.36% of the company’s shares, while institutions hold 8.92% stake in the company. Shares short for CVAC as of 1764288000 were 1659938 with a Short Ratio of 1.93, compared to 1761868800 on 801715. Therefore, it implies a Short% of Shares Outstanding of 1659938 and a Short% of Float of 1.48.
Earnings Estimates
Its stock is currently analyzed by 2.0 different market analysts.
Analysts are recommending an EPS of between -$0.26 and -$0.71 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.5, with 4.0 analysts recommending between -$0.26 and -$0.73.
Revenue Estimates
According to 2 analysts,. The current quarter’s revenue is expected to be $13.35M. It ranges from a high estimate of $24.7M to a low estimate of $2M. As of. The current estimate, CureVac N.V’s year-ago sales were $14.5M
A total of 4 analysts have provided revenue estimates for CVAC’s current fiscal year. The highest revenue estimate was $90.85M, while the lowest revenue estimate was $34.14M, resulting in an average revenue estimate of $62.79M. In the same quarter a year ago, actual revenue was $535.2MBased on 5 analysts’ estimates, the company’s revenue will be $88.19M in the next fiscal year. The high estimate is $105.99M and the low estimate is $61.2M.
